Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 18/20 | 0.84 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.84 |
| ▸ | PIK3CD | O00329 | 13/20 | 0.84 |
| ▸ | PIK3R1 | P27986 | 12/20 | 0.84 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2818070 | 0.91 | PIK3CB (1.00) | PIK3CBPIK3CAPIK3CDPIK3R1PIK3CG | |
| SCHEMBL3569964 | 0.87 | PIK3CB (0.83) | PIK3CBPIK3CAPIK3CDPIK3R1 | |
| SCHEMBL2816007 | 0.86 | PIK3CB (1.00) | PIK3CBPIK3CAPIK3CDPIK3R1PIK3CG | |
| SCHEMBL3568141 | 0.84 | PIK3CB (1.00) | PIK3CBPIK3CAPIK3CDPIK3R1PIK3CG | |
| SCHEMBL477288 | 0.84 | PIK3CB (0.85) | PIK3CBPIK3CAPIK3CDPIK3R1PIK3CG | |
| SCHEMBL2812275 | 0.82 | PIK3CB (1.00) | PIK3CBPIK3CAPIK3CDPIK3R1PIK3CG | |
| SCHEMBL2819585 | 0.81 | PIK3CB (1.00) | PIK3CBPIK3CAPIK3CDPIK3R1PIK3CG | |
| SCHEMBL2954940 | 0.81 | PIK3CB (0.79) | PIK3CBPIK3CAPIK3CDPIK3R1PIK3CG | |
| SCHEMBL2956479 | 0.81 | PIK3CB (1.00) | PIK3CBPIK3CAPIK3CDPIK3R1PIK3CG | |
| SCHEMBL2814733 | 0.81 | PIK3CB (1.00) | PIK3CBPIK3CAPIK3CDPIK3R1PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010110686-A1 | PYRIMIDINYL AND 1,3,5 TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-09-30 | — | — | WO | disclosed |